Literature DB >> 16679722

Protective effect of botulinum C/D mosaic toxoid against avian botulism.

Masato Takeda1, Hiroko Kasai, Yasushi Torii, Masafumi Mukamoto, Tomoko Kohda, Kentaro Tsukamoto, Shunji Kozaki.   

Abstract

Avian botulism is a paralytic disease caused by a toxin produced by Clostridium botulinum type C. Since type C isolates from cases of avian botulism produced a neurotoxin consisting of a mosaic form of parts of type C and D neurotoxins, we examined the antitoxin titers in the convalescent sera of botulism-affected birds which belonged to family Anatidae. ELISA using the C/D mosaic neurotoxin as an antigen revealed that the antibody was detected in the sera at 2 weeks, but not at 5 weeks after the onset, suggesting that the antibody only appeared for a short period in the convalescent phase. However, we failed to detect the antibody titers with anti-chicken IgG instead of anti-duck IgG. We therefore examine the immunological properties of IgG among different families and species. The results revealed that different species of IgG in the same family exhibited strong cross-reactivity. Ducks immunized once with the toxoid together with a commercial oil-adjuvanted vaccine were found to develop sufficient antibody to protect against a challenge with a lethal toxin dose. The ELISA titers did not correspond to the neutralization titers in the sera of immunized ducks at the early stage during immunization. These findings suggest that the neutralizing titer was more useful than the ELISA titer for evaluating the protection against the toxin, but the ELISA technique may be applicable for detecting the occurrence of botulism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679722     DOI: 10.1292/jvms.68.325

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  6 in total

1.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

2.  Multiplex real-time PCR for detecting and typing Clostridium botulinum group III organisms and their mosaic variants.

Authors:  Fabrizio Anniballi; Bruna Auricchio; Cédric Woudstra; Patrick Fach; Alfonsina Fiore; Hanna Skarin; Luca Bano; Bo Segerman; Rickard Knutsson; Dario De Medici
Journal:  Biosecur Bioterror       Date:  2013-09

3.  A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication.

Authors:  Chi Ho Yu; Dong Hyun Song; Jun Young Choi; Hae Eun Joe; Woo Hyeon Jeong; Gyeung Haeng Hur; Young Kee Shin; Seong Tae Jeong
Journal:  Hum Vaccin Immunother       Date:  2017-12-19       Impact factor: 3.452

4.  Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Authors:  Luciana A F Gil; Carlos Eduardo P da Cunha; Gustavo M S G Moreira; Felipe M Salvarani; Ronnie A Assis; Francisco Carlos F Lobato; Marcelo Mendonça; Odir A Dellagostin; Fabricio R Conceição
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

Review 5.  Vaccines against Botulism.

Authors:  Grace Sundeen; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2017-09-02       Impact factor: 4.546

6.  An adenoviral vector-based mucosal vaccine is effective in protection against botulism.

Authors:  Q Xu; M E Pichichero; L L Simpson; Md Elias; L A Smith; M Zeng
Journal:  Gene Ther       Date:  2009-01-08       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.